Philadelphia Chromosome Positive Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03512405Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaTreatment